The phase III PAPILLON study (n = 308) established amivantamab plus chemotherapy as a first-line standard for EGFR ex20in NSCLC, showing superior mPFS (11.4 vs. 6.7 months; HR 0.40, p < 0.001), ORR (73% vs. 43%), and DOR (9.7 vs. 4.4 months) over CTlone [59]. Here, EGFR is linked to non-small cell lung carcinoma.